When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Capricor Therapeutics (CAPR) is a small biotechnology company focused on the treatment of Duchenne muscular dystrophy ((DMD)) which saw major action on Monday 15 July as it more than doubled from under $4 to over $8 as it announced positive results from its interim analysis of its so-called HOPE-2 trial (a randomized, double-blind, placebo-controlled Phase II trial of CAP-1002, CAPR's lead investigational therapy). While there is some value in this news, it is my view that those investing in CAPR at roughly double its prior price are taking on significant risk given CAPR's